Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs, Inc. (NASDAQ: BIOA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic diseases by targeting the biology of human aging. Company announcements highlight progress in its lead NLRP3 inhibitor program, preclinical obesity programs, and collaborations with larger pharmaceutical partners.
A key focus of recent news is BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor. BioAge has reported interim data from an ongoing Phase 1 single and multiple ascending dose trial, including information on safety, pharmacokinetics, and pharmacodynamic effects on inflammatory biomarkers such as IL-1β, hsCRP, IL-6, and fibrinogen in healthy volunteers and obese participants with elevated inflammation.
News updates also cover BioAge’s broader pipeline and strategy. The company issues releases on the advancement of long-acting injectable and oral small-molecule APJ agonists for obesity, including a nanobody APJ agonist under an exclusive option agreement and a portfolio of orally active APJ agonists. In addition, BioAge communicates developments in its discovery platform based on human longevity data and its multi-year collaborations with Novartis and Lilly ExploR&D on metabolic aging targets.
Investors following BIOA news can expect coverage of clinical milestones for BGE-102, preclinical and regulatory progress for APJ agonist programs, financial results, and participation in healthcare and biotechnology conferences. This page aggregates those updates so readers can review BioAge’s clinical data disclosures, partnership announcements, and strategic commentary in one place.
FAQ
What is the current stock price of BioAge Labs (BIOA)?
What is the market cap of BioAge Labs (BIOA)?
